Holen Sie sich die Stockscreener-App
548.62
2.02%
-9.29
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
The Goldman Sachs Group Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA - Ophthalmology Times
Complement Inhibitors Market 2024 Edition: Size, Share, Trends - openPR.com
What to Expect From Regeneron's Next Quarterly Earnings Report - TradingView
Savvy Advisors Inc. Acquires Shares of 1,245 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron: Still A Biotech Juggernaut (NASDAQ:REGN) - Seeking Alpha
F M Investments LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Heritage Trust Co Invests $1.72 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study - Benzinga
Thyroid Eye Disease Market Predicted to See Upsurge Through - openPR.com
What To Expect From Regeneron's Next Quarterly Earnings Report - Barchart.com
Biocon achieves settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US - Ophthalmology Times
Taurus Asset Management LLC Acquires 1,130 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Rockefeller Capital Management L.P. Sells 3,260 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Biocon Biologics secures market entry date for ophthalmology drug Yesafili in US - Medical Dialogues
Neutralizing Antibody Market Set to Witness Significant Growth - openPR.com
Biocon Biologics' Yesafili to enter US market, following agreement with Regeneron - Times of India
Kennedy Capital Management LLC Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers - The Globe and Mail
ExodusPoint Capital Management LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $917.00 by Analysts at The Goldman Sachs Group - Defense World
Biocon Biologics Secures US Market Entry for Yesafili - Rediff MoneyWiz
Biocon Biologics signs US settlement with Regeneron to Launch Yesafili Biosimilar by 2026 - Express Pharma
Treasurer of the State of North Carolina Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Boosted by FIL Ltd - MarketBeat
Envestnet Asset Management Inc. Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Distillate Capital Partners LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN) - Yahoo Finance
CenterBook Partners LP Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
FDA Action Alert: Regeneron, Sanofi and Abeona - BioSpace
Bank of Nova Scotia Sells 8,529 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Martingale Asset Management L P Reduces Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bank of Montreal Can Has $109.18 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
APG Asset Management N.V. Purchases 59,984 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
679 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Coign Capital Advisors LLC - MarketBeat
Renaissance Technologies LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 52-Week LowHere's Why - MarketBeat
Invesco Ltd. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Wells Fargo & Company MN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Legal & General Group Plc - MarketBeat
Peapack Gladstone Financial Corp Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Massachusetts Financial Services Co. MA Cuts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Amgen’s Bundling Antitrust Case Against Regeneron Proceeds - USA Herald
Cerity Partners LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by ADAR1 Capital Management LLC - MarketBeat
Amgen Can't Ditch Regeneron's Bundling Antitrust Suit - Law360
Russell Investments Group Ltd. Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Citigroup Adjusts Price Target on Regeneron Pharmaceuticals to $600 From $750, Keeps Neutral Rating - MarketScreener
Next Generation Immunotherapies Market Growth Projections - openPR.com
Goldman Sachs Cuts Price Target on Regeneron Pharmaceuticals to $917 From $1,019, Keeps Buy Rating - MarketScreener
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Federated Hermes Inc. - MarketBeat
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies - Benzinga
Regeneron (REGN) Price Target Cut by Guggenheim Prior to Q1 Earnings | REGN Stock News - GuruFocus
Central Retinal Vein Occlusion Therapeutics Market Size in 7MM - openPR.com
Ilmarinen Mutual Pension Insurance Co Buys 3,400 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $940 From $950, Maintains Buy Rating - MarketScreener
Prostate Cancer Pipeline Analysis and Clinical Trials - openPR.com
1.70%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):